Table 4 Some mucin-based and other emerging therapies for ovarian cancer treatment [88–94]
Antibody targeting | Vaccines | ||
|---|---|---|---|
| Â | Antibody-based | Antigen-based | Cell-based |
Anti-HER2/neu antibody (Herceptin) [In use] | Idiotypic vaccination with anti-MUC1 HMFG1MAb [Phase I trial] | MUC1 presenting Immunogens [Phase I] | Fusions of ovarian carcinoma cells and dendritic cells (DC) [Preclinical] |
90Y-labelled anti-MUC1 HMFG1 MAb [Phase 1] | Anti-CA-125 B43.13 MAb vaccine (OvaRex) [Phase IIb] | Peptides derived from a folate binding protein [Phase 1] | MUC1 RNA transfected dendritic cells [Preclinical] |
131I-labelled OC125 MAb [Phase I/II] | Anti-idiotypic antibody ACA-125 vaccine [Phase I/II] | Synthetic Lewis (y)-protein conjugate vaccine [Phase 1] | Genetically engineered GM-CSF producing tumor cells |
131I-labelled MOv8 chimeric MAb [Phase 1] | Â | Her2/neu presenting peptides vaccines [Phase 1] | Her2/neu and MUC1 peptide pulsed dendritic cells [Pilot study] |
Nano-RIT with CA125 and anti-HER2 MAb [Under investigation] | Â | Theratope STn-KLH cancer vaccine [Phase 1] | Dendritic cells pulsed with tumor-lysate |